• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

June 5, 2025 | 62nd ERA Congress
Kirk Rowley, et al.

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

Kirk Rowley, Vinay Singh, Anna Roberts, Katie Heang, Prashanna Venkatasubramanian, Jacob Konaklonda, Daved Fared, Michelle Lu, Brett Hurst, Wayne W. Hancock, Gregory J. Babcock, Luke Robinson

>SEE POSTER

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk